Efficacy of anti-interleukin-6 receptor antibody (tocilizumab) in colombian patients with takayasu’s arteritis

Background Takayasu’s arteritis (TA) is a chronic vasculitis that involves aorta and its main branches, where interleukin-6 (IL-6) seems to play a pathogenic role (1,2). The effect in four patients treated with the anti-IL-6 receptor (IL-6R) antibody Tocilizumab was evaluated. Objectives to describe the effect of Tocilizumab in patients of Takayasu’s arteritis. Methods We reviewed the clinical records of 4 patients with TA diagnosed according to current criteria, treated between 2010 and 2011 in a tertiary center in Cali, Colombia. Four patients with a refractory disease to multiple treatments, was began treatment with Tocilizumab at a dose of 8 mg/kg every month in association with metothrexate and/or steroids. Two patients were treated previously with infliximab (IFX) without control of disease. This cases were reported previously (3). Results The cases summaries are as follows: Case 1. A 30 year-old woman with a diagnosis of TA since 2003 presented panaortitis, with involvement of supra-aortic,

• Autores: Izquierdo, Jorge H.; Cañas Dávila, Carlos Alberto; Bonilla Abadía, Fabio
• Tipo de recurso: http://purl.org/coar/resource_type/c_c94f
• Fecha de publicación: 2013
• Institución: Universidad ICESI
• Repositorio: Repositorio ICESI
• Idioma: eng
• OAI Identifier: oai:repository.icesi.edu.co:10906/82270
• Acceso en línea: http://hdl.handle.net/10906/82270; http://dx.doi.org/10.1136/annrheumdis-2012-eular.743
• Palabra clave: Arteritis de Takayasu; Ciencias socio biomédicas; Medical sciences; Vasculitis; Interleucina-6; Tratamiento farmacológico
• Rights: openAccess
• License: https://creativecommons.org/licenses/by-nc-nd/4.0/